Nicotinic acid in the prevention and treatment of methionine-induced exacerbation of psychopathology in schizophrenics.
D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008715:Methionine / Q000008:administration & dosage*; D008717:Methionine Sulfoximine / Q000009:adverse effects; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000517:prevention & control*; D014191:Tranylcypromine / Q000008:administration & dosage
D009539:Nicotinic Acids; D010919:Placebos; D008717:Methionine Sulfoximine; D014191:Tranylcypromine; D008715:Methionine